Biotech Values

[mr_o]

Insulin Resistance & Type 2 Diabetes: A new paradigm

Listened to The Drive Podcast, Peter Attia and Jason Fung on "Fasting as a potent antidote to obesity, insulin resistance, type 2 diabetes, and the many symptoms of metabolic illness".

https://peterattiamd.com/jasonfung/

"We think of all these responses, obesity, insulin resistance, and the beta cell failure, as pathologic. They're actually protective. . .Your body is actually trying to protect itself against the root cause of the problem which is too much insulin, too much glucose."

One of the key points made is that insulin resistance is a protective feature of cells. Type 2 diabetic's have cells that are full of glucose and therefore become resistant to insulin (which signals to put more glucose into the cells). If we think of total body glucose as opposed to HbA1c (bloodstream glucose) the idea makes more sense. The functional conclusion is that this is why SLGT2 inhibitors and fasting are the best approaches to lowering total body glucose, and not just HbA1c. I am sure I am doing the podcast a disservice by trying to sum the ideas into a small paragraph so I urge everyone to listen. If true, the ideas are worth understanding.

To tie into biotech values, this may have long term impact on Novo and Eli if this idea is true and catches on. However, asking the general public to fast instead of taking medicine is likely harder than turning the titanic.